Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lecomte

Showing results (471-480 of 481) with videos related to

Pageof 49
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 1, 1996
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC)M Borges, J P Sculier, M Paesmans, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2004
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapyT Berghmans, J J Lafitte, J Thiriaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2008
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancerJ P Sculier, J J Lafitte, A Efremidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2007
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
British Journal of Cancer|November 27, 2001
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibioticsJ P Sculier, M Paesmans, J Lecomte, et al.
International Journal of Oncology|May 11, 2011
A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancerJ Sculier, J Thiriaux, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancerJ-P Sculier, J-J Lafitte, T Berghmans, et al.
British Journal of Cancer|May 3, 2007
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyT Berghmans, J J Lafitte, J Lecomte, et al.
Circulation Research|September 27, 2008
Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthaseAndrew J Webb, Alexandra B Milsom, Krishnaraj S Rathod, et al.
The European Respiratory Journal|August 11, 2007
Chemotherapy improves low performance status lung cancer patientsJ P Sculier, J J Lafitte, M Paesmans, et al.
Pageof 49

Showing results (471-480 of 481) with videos related to

Sort By:
Pageof 49
Lung Cancer (Amsterdam, Netherlands)|December 1, 1996
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC)M Borges, J P Sculier, M Paesmans, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2004
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapyT Berghmans, J J Lafitte, J Thiriaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2008
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancerJ P Sculier, J J Lafitte, A Efremidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2007
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
British Journal of Cancer|November 27, 2001
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibioticsJ P Sculier, M Paesmans, J Lecomte, et al.
International Journal of Oncology|May 11, 2011
A phase-ii study testing weekly platinum derivative combination chemotherapy as 2nd-line treatment in patients with advanced small-cell lung-cancerJ Sculier, J Thiriaux, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancerJ-P Sculier, J-J Lafitte, T Berghmans, et al.
British Journal of Cancer|May 3, 2007
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyT Berghmans, J J Lafitte, J Lecomte, et al.
Circulation Research|September 27, 2008
Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthaseAndrew J Webb, Alexandra B Milsom, Krishnaraj S Rathod, et al.
The European Respiratory Journal|August 11, 2007
Chemotherapy improves low performance status lung cancer patientsJ P Sculier, J J Lafitte, M Paesmans, et al.
Pageof 49